Ardsley Advisory Partners Acquires New Stake in Myovant Sciences Ltd (MYOV)

Ardsley Advisory Partners acquired a new stake in shares of Myovant Sciences Ltd (NYSE:MYOV) in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 100,000 shares of the company’s stock, valued at approximately $1,272,000. Ardsley Advisory Partners owned about 0.16% of Myovant Sciences as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. JPMorgan Chase & Co. raised its position in shares of Myovant Sciences by 18.4% during the third quarter. JPMorgan Chase & Co. now owns 91,213 shares of the company’s stock valued at $1,382,000 after buying an additional 14,203 shares during the last quarter. Point72 Asset Management L.P. acquired a new position in shares of Myovant Sciences during the third quarter valued at about $1,255,000. Finally, Goldman Sachs Group Inc. acquired a new position in shares of Myovant Sciences during the second quarter valued at about $174,000. 81.44% of the stock is owned by institutional investors and hedge funds.

Myovant Sciences Ltd (NYSE MYOV) opened at $16.92 on Tuesday. Myovant Sciences Ltd has a 52-week low of $9.92 and a 52-week high of $18.85. The company has a debt-to-equity ratio of 0.35, a current ratio of 5.04 and a quick ratio of 5.04. The stock has a market cap of $1,040.00 and a PE ratio of -8.63.

Myovant Sciences (NYSE:MYOV) last posted its quarterly earnings results on Tuesday, February 13th. The company reported ($0.70) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.42) by ($0.28). analysts expect that Myovant Sciences Ltd will post -2.07 EPS for the current fiscal year.

MYOV has been the subject of a number of research analyst reports. Cowen reaffirmed a “buy” rating on shares of Myovant Sciences in a research report on Tuesday, November 14th. Zacks Investment Research raised shares of Myovant Sciences from a “sell” rating to a “hold” rating in a research report on Wednesday, January 17th. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the company. Myovant Sciences has a consensus rating of “Buy” and a consensus price target of $22.50.

COPYRIGHT VIOLATION NOTICE: This report was first reported by American Banking News and is the property of of American Banking News. If you are accessing this report on another publication, it was illegally stolen and republished in violation of US & international copyright and trademark legislation. The original version of this report can be accessed at

Myovant Sciences Company Profile

Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for women’s health diseases and other endocrine-related disorders. Its main product candidate is Relugolix. Relugolix is an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and inhibits receptors in the anterior pituitary gland.

Institutional Ownership by Quarter for Myovant Sciences (NYSE:MYOV)

Receive News & Ratings for Myovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myovant Sciences and related companies with's FREE daily email newsletter.

Leave a Reply